| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/22/2003 | EP1277753A1 Thiazolidinedione derivative and its use as antidiabetic |
| 01/22/2003 | EP1277752A1 Process for producing optically active sulfoxide derivative |
| 01/22/2003 | EP1277750A1 Hydrates and crystals of a neuraminic acid compound |
| 01/22/2003 | EP1277747A1 Selective preventives/remedies for progressive lesions after organ damage |
| 01/22/2003 | EP1277746A2 N-benzylpiperazine derivatives, process for their preparation and pharmaceutical compositions thereof |
| 01/22/2003 | EP1277744A1 Oxadiazole derivatives having anticancer effects |
| 01/22/2003 | EP1277743A1 Oxa(thia)zolidine derivative and anti-inflammatory drug |
| 01/22/2003 | EP1277738A1 Condensed heteroaryl derivatives |
| 01/22/2003 | EP1277730A1 Neovascularization inhibitors |
| 01/22/2003 | EP1277729A1 Ppar (gamma) modulators |
| 01/22/2003 | EP1277478A1 Medicinal compositions for suppressing beta-amyloid production |
| 01/22/2003 | EP1277477A2 Treatment of neurodegenerative diseases and the effects of aging |
| 01/22/2003 | EP1277475A1 Bone-strengthening agents, food compositions for strengthening bone and feed compositions for strengthening bone |
| 01/22/2003 | EP1277473A1 Remedies |
| 01/22/2003 | EP1277472A1 Remedies for cancer |
| 01/22/2003 | EP1277471A1 Stable liquid preparation |
| 01/22/2003 | EP1277470A1 Injectable galenical formulation for use in photodynamic diagnostic or therapy and process of manufacturing it |
| 01/22/2003 | EP1277469A1 Activators for peroxisome proliferator-activated receptor |
| 01/22/2003 | EP1277468A1 Compositions for promoting sleep |
| 01/22/2003 | EP1277467A2 Non-chlorofluorocarbon aerosol formulations |
| 01/22/2003 | EP1277466A1 Patch containing anti-inflammatory agent |
| 01/22/2003 | EP1276897A2 Live cell procedures to identify compounds modulating intracellular distribution of phosphodiesterase (pde) enzymes |
| 01/22/2003 | EP1276893A1 Purified and isolated potassium-chloride cotransporter nucleic acids and polypeptides and therapeutic and screening methods using same |
| 01/22/2003 | EP1276887A2 Protection against environmental toxicity through manipulation of the processing of messenger rna precursors |
| 01/22/2003 | EP1276872A2 A thymus expressed human cytochrome p450 (p450tec) |
| 01/22/2003 | EP1276750A1 Antisense modulation of zinc finger protein-217 expression |
| 01/22/2003 | EP1276749A1 Novel, photo-labile cumarinylmethyl esters of cyclic nucleotides, method for the production and use thereof |
| 01/22/2003 | EP1276747A1 The use of azalide antibiotic compositions for treating or preventing a bacterial or protozoal infection in mammals |
| 01/22/2003 | EP1276742A2 Process for the preparation of pyrazolopyridine derivatives |
| 01/22/2003 | EP1276740A2 Novel epothilone derivatives, method for the preparation thereof and their pharmaceutical use |
| 01/22/2003 | EP1276739A2 Heterocycles that are inhibitors of impdh enzyme |
| 01/22/2003 | EP1276738A1 2-amino-3-(alkyl)-pyrimidone derivatives as gsk3.beta. inhibitors |
| 01/22/2003 | EP1276737A1 Sodium-hydrogen exchanger type 1 inhibitor (nhe-1) |
| 01/22/2003 | EP1276736A2 Regioselective synthesis of 3,4-di(carbocyclyl or heterocyclyl)thiophenes |
| 01/22/2003 | EP1276734A1 Halogenated rhodamine derivatives and applications thereof |
| 01/22/2003 | EP1276731A2 Branched adamantyl and noradamantyl aryl- and aralkylpiperazines with serotonin 5-ht 1a activity |
| 01/22/2003 | EP1276730A2 Thiazolidinedione analogues and their use for the treatment of diabetes |
| 01/22/2003 | EP1276729A1 New neurokinin antagonists for use as medicaments |
| 01/22/2003 | EP1276728A2 Ultrashort acting hypnotic barbiturates |
| 01/22/2003 | EP1276726A2 Substituted phenyl farnesyltransferase inhibitors |
| 01/22/2003 | EP1276725A2 5-substituted tetralones as inhibitors of ras farnesyl transferase |
| 01/22/2003 | EP1276724A2 Dihydro-2h-naphthalene-1-one inhibitors of ras farnesyl transferase |
| 01/22/2003 | EP1276723A2 Pyrazole compounds having anti proliferative activity |
| 01/22/2003 | EP1276722A1 Naphthamidine urokinase inhibitors |
| 01/22/2003 | EP1276720A2 2-acyl indol derivatives and their use as anti-tumour agents |
| 01/22/2003 | EP1276718A2 Small technetium-99m and rhenium labeled agents and methods for imaging tumors |
| 01/22/2003 | EP1276714A2 Cyclic carboxylic acids as integrin antagonists |
| 01/22/2003 | EP1276713A1 Inhibition of angiogenesis and tumor growth |
| 01/22/2003 | EP1276710A1 New compounds, their preparation and use |
| 01/22/2003 | EP1276672A2 Improved method and apparatus for generating an aerosol |
| 01/22/2003 | EP1276504A2 Medicines for treating tumoral pathologies containing the ro5-4864 compound and an apoptosis-inducing agent |
| 01/22/2003 | EP1276503A2 Compositions comprising an inhibitor of an acrab-like efflux pump for reducing microbial resistance to drugs |
| 01/22/2003 | EP1276502A1 Single-dose antihistamine/decongestant formulations for treating rhinitis |
| 01/22/2003 | EP1276497A2 Mixture of defibrotide and g-csf and its use for activating haematopoietic progenitors |
| 01/22/2003 | EP1276496A2 Combined treatment with keratinocyte growth factor and epidermal growth factor inhibitor |
| 01/22/2003 | EP1276494A1 A memory enhancing protein |
| 01/22/2003 | EP1276489A1 Novel medicines based on sesquiterpene mixtures |
| 01/22/2003 | EP1276485A2 Compositions useful in the treatment of diseases of connective tissues comprising a ferrous ion and an ascorbate |
| 01/22/2003 | EP1276484A2 Medicine containing polysaccharide substances for activating apoptosis |
| 01/22/2003 | EP1276483A2 Compositions and methods for treating amyloidosis using sulphonate derivatives |
| 01/22/2003 | EP1276482A2 Combination chemotherapy |
| 01/22/2003 | EP1276481A2 Daily treatment for erectile dysfunction using a pde5 inhibitor |
| 01/22/2003 | EP1276480A1 Process of making racemic bupivacaine's enantiomers, levobupivacaine's pharmaceutical compositions, levobupivacaine's pharmaceutical compositions formulated on its free base form or its pharmaceutical acceptable salts and use of levobupivacaine's pharmaceutical compositions formulated on its free ba |
| 01/22/2003 | EP1276479A2 Inhibition of abnormal cell proliferation with camptothecin and combinations including the same |
| 01/22/2003 | EP1276478A2 (2-aminoethyl) oxime derivatives for the treatment of depression |
| 01/22/2003 | EP1276477A2 Medicaments containing pantothenic acid for the treatment of inflammatory joint disease |
| 01/22/2003 | EP1276476A2 Use of bradycardiac substances in the treatment of myocardial diseases associated with hypertrophy and novel medicament combinations |
| 01/22/2003 | EP1276475A2 Topical anesthetic/opioid formulations and uses thereof |
| 01/22/2003 | EP1276474A2 Formulations for use in inhaler devices |
| 01/22/2003 | EP1276473A2 Pharmaceutical formulations for dry powder inhalers |
| 01/22/2003 | EP1276472A2 Formulations for use in inhaler devices |
| 01/22/2003 | EP1276471A2 Membrane delivery system |
| 01/22/2003 | EP1276469A2 Taste masking coating composition |
| 01/22/2003 | EP1276467A2 Guaifenesin sustained release formulation and tablets |
| 01/22/2003 | EP1276465A2 Improved water-insoluble drug particle process |
| 01/22/2003 | EP1276463A1 Hemostatic agent, method and carrier for applying a blood clotting agent |
| 01/22/2003 | EP1276462A2 Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof |
| 01/22/2003 | EP1276460A1 Cosmetic and/or pharmaceutical preparations that contain an extract of the plant argania spinosa |
| 01/22/2003 | EP1276459A1 Cosmetic or dermatological cream composition, the preparation and the use thereof |
| 01/22/2003 | EP1276392A2 Nutritional modules |
| 01/22/2003 | EP1276376A1 Active substance combinations with insecticidal and acaricidal properties |
| 01/22/2003 | EP1242079A4 Methods of use of fluoroquinolone compounds againts bacteria |
| 01/22/2003 | EP1175154A4 Method for manufacturing rumen bypass feed supplement |
| 01/22/2003 | EP1165537B1 Hydroxymatairesinol in cancer prevention |
| 01/22/2003 | EP1158963B1 Controlled-release compositions of betahistine |
| 01/22/2003 | EP1107738A4 Novel pharmaceutical salt form |
| 01/22/2003 | EP1084129B1 Cyclic boroproline compounds |
| 01/22/2003 | EP1079834B1 Stable compositions comprising levosimendan and alginic acid |
| 01/22/2003 | EP1070078B1 Form vi 5,6-dichloro-2-(isopropylamino)-1-beta-l-ribofuranosyl)-1h-benzimidazole |
| 01/22/2003 | EP1030835B1 Urea derivatives and their use as integrin inhibitors |
| 01/22/2003 | EP0973774B1 1,5-dihydro-pyrazolo 3,4-d]-pyrimidinone derivatives |
| 01/22/2003 | EP0968213B1 Alkynyl-substituted camptothecins and process for their preparation |
| 01/22/2003 | EP0968174B1 Optically active 2-aminotetraline, process for its preparation and pharmaceutical compositions containing same, active in preventing and treating septic shock |
| 01/22/2003 | EP0942721B1 Liquid composition comprising an hiv protease inhibitor and a c12-c18 fatty acid |
| 01/22/2003 | EP0937085B1 Magnesium (-)hydroxycitrate, method of preparation, applications, and compositions in particular pharmaceutical containing same |
| 01/22/2003 | EP0909174A4 Treatment of cystic disease with tnf-alpha |
| 01/22/2003 | EP0908467B1 Use of the hot-water extract of ''nemacystus decipiens'' |
| 01/22/2003 | EP0898562B1 Hydroxamic acid derivatives for use with the treatment of diseases related to connective tissue degradation |
| 01/22/2003 | EP0865339B1 Metalloproteinase inhibitors |
| 01/22/2003 | EP0854731B1 Copolymeric micelle drug composition and method for the preparation thereof |